PHIO — Phio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Phio Pharmaceuticals Announces Positive Recommendation From Safety Monitoring Committee Of Phase 1B Clinical Study Of Phio S Lead Compound Ph-762
Brief: Phio Pharmaceuticals Corp Files For Mixed Shelf Of Up To $100 Mln
Brief: Phio Pharmaceuticals Files For Mixed Shelf Of $100 Mln
Brief: Phio Pharmaceuticals Secures New Investor
Brief: Intratumoral Injection Of Phio’S Ph-762 Significantly Inhibits Tumor Growth In Murine Tumor Models And May Generate Memory-Specific T Cells
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share - Earnings Preview
Brief: Phio Pharmaceuticals Presenting Data Showing Intasyl May Result In More Effective Cell Therapy For Hematological Malignancies
Phio Pharmaceuticals Corp expected to post a loss of $1.30 a share - Earnings Preview
Brief: Phio Pharmaceuticals Corp Says It Receives Non-Compliance Notice From Nasdaq - SEC Filing
Brief: Phio Pharmaceuticals Announces Dosing Of First Patient In Collaborative Clinical Trial With Agonox And Providence Cancer Institute
Brief: Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Nvidia, GeoVax Labs, Freshpet
U.S. STOCKS ON THE MOVE-Citigroup, Tigo Energy, Children's Place
U.S. STOCKS ON THE MOVE-Shoe Carnival, Intuit, Abercrombie & Fitch
Phio Pharma gains as company says it can start patient enrollment for lead drug trial
Brief: Phio Pharmaceuticals Announces Initiation Of Collaborative Clinical Trial With PH-762, Agonox's Tumor Infiltrating Lymphocyte Program (AGX148) And Providence Cancer Institute
Phio Pharma gains on FDA nod to start clinical trial of lead drug
Brief: Phio Pharmaceuticals Announces FDA Clearance To Initiate Clinical Trial Of Ph-762 For Treatment Of Skin Carcinomas
Brief: Phio Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Business Update